Author

J. Zerbib

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 6 Bioengineering· 1 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 7 Assay:bulk RNA-seq· 5 Approach:experimental assay· 4 Approach:statistical model· 4 Research Focus:differential expression· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell type annotation· 2 Research Focus:chromatin & epigenetic regulation· 2

Frequent Co-Authors

U. Ben-David· 7 shared K. Laue· 3 shared M. R. Ippolito· 3 shared S. Santaguida· 3 shared Y. Cohen-Sharir· 3 shared Y. Eliezer· 3 shared A. S. Kadmon· 2 shared E. Reuveni· 2 shared

Activity by Year

2020-2024 · peak 6/yr

Co-Author Collaboration Network

10 top collaborators · 39 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

7 shared papersCancer Biology

U. Ben-David

Mutual co-authors in cluster

Author profile →

8 papers

Recent·Most cited

Chromosome 7 to the rescue: overcoming chromosome 10 loss in gliomas

N. U. Nair, A. A. Schaffer, M. E. Gertz, K. Cheng, J. Zerbib, A. D. Sahu, G. Leor, E. D. Shulman, K. D. Aldape, U. Ben-David, E. Ruppin

The paper investigates the co-occurrence of chromosome 10 loss and chromosome 7 gain in gliomas, finding functional rescue interactions on chromosome 7 that may compensate for chromosome 10 loss.

bioRxiv · Jan 17, 2024 · PreprintCancer Biology

Inactivation of p53 drives breast cancer brain metastasis by altering fatty acid metabolism

K. Laue, S. Pozzi, Y. Cohen-Sharir, T. Winkler, Y. Eliezer, S. Israeli Dangoor, A. Leikin-Frenkel, K. Lange, J. Zerbib, A. A. Ricci, A. Sacconi, J. Berthelet, A. Schaffer, W. Shi, Y. Liao, , U. Ben-David

This study shows that p53 inactivation promotes breast cancer brain metastasis by altering fatty acid metabolism, with implications for therapeutic targeting.

bioRxiv · Dec 20, 2023 · PreprintCancer Biology

A compendium of Amplification-Related Gain Of Sensitivity (ARGOS) genes in human cancer

V. Rendo, M. Schubert, N. Khuu, M. F. Suarez Peredo Rodriguez, K. Huang, M. Swift, Y. He, J. Zerbib, R. Smith, J. Raaijmakers, P. Bandopadhayay, L. M. Guenther, J. H. Hwang, A. Iniguez, S. Moody, , F. Foijer

The paper identifies ARGOS genes, which are amplified in cancer, have low expression relative to copy number, and are toxic when overexpressed, and validates several as pan-cancer targets.

bioRxiv · Dec 16, 2023 · PreprintCancer Biology

Cytogenetic resource enables mechanistic resolution of changing trends in human pluripotent stem cell aberrations linked to feeder-free culture

D. Stavish, C. J. Price, G. Gelezauskaite, K. A. Leonhard, S. M. Taapken, E. M. McIntire, O. Laing, B. M. James, J. J. Riley, J. Zerbib, D. Baker, A. L. Harding, L. H. Jestice, T. F. Eleveld, A. J. M. Gillis, , I. Barbaric

The paper analyzes genetic changes in human pluripotent stem cells under different culture conditions and identifies a link between feeder-free culture and increased chromosome 1q gains.

bioRxiv · Sep 21, 2023 · PreprintCell Biology

Computationally Engineered CRISPR-SpyCas9 High-Fidelity Variants with Improved Specificity and Reduced Non-specific DNA Damage

R. Rabinowitz, O. Shor, J. Zerbib, S. Herman, N. Zelikson, S. Madiwale, N. Yom-Tov, U. Ben-David, F. Benninger, D. Offen

The paper develops ComPE, a computational method to engineer high-fidelity CRISPR-Cas9 variants with improved specificity and reduced off-target effects.

bioRxiv · Apr 11, 2023 · PreprintBioengineering

Human aneuploid cells depend on the RAF/MEK/ERK pathway for overcoming increased DNA damage

J. Zerbib, M. R. Ippolito, Y. Eliezer, G. De Feudis, E. Reuveni, A. S. Kadmon, S. Martin, S. Vigano', G. Leor, J. Berstler, K. Laue, Y. Cohen-Sharir, S. Scorzoni, F. Vazquez, U. Ben-David, S. Santaguida

This study identifies the RAF/MEK/ERK pathway as a critical dependency for aneuploid cells, showing increased pathway activity and sensitivity to its inhibition in aneuploid cancer cells.

bioRxiv · Jan 27, 2023Cancer Biology

Increased RNA and protein degradation is required for counteracting transcriptional burden and proteotoxic stress in human aneuploid cells

M. R. Ippolito, J. Zerbib, Y. Eliezer, E. Reuveni, S. Vigano', G. De Feudis, A. S. Kadmon, I. Vigorito, S. Martin, K. Laue, Y. Cohen-Sharir, S. Scorzoni, F. Vazquez, S. Santaguida, U. Ben-David

This study identifies increased RNA and protein degradation as mechanisms by which aneuploid cells counteract transcriptional burden and proteotoxic stress, revealing potential therapeutic targets.

bioRxiv · Jan 27, 2023Cancer Biology

Aneuploidy-driven genome instability triggers resistance to chemotherapy

M. R. Ippolito, V. Martis, C. Hong, R. Wardenaar, J. Zerbib, D. C. J. Spierings, U. Ben-David, F. Foijer, S. Santaguida

This study shows that aneuploidy-induced genome instability helps cancer cells resist chemotherapy by enabling survival under drug pressure.

bioRxiv · Sep 25, 2020 · PreprintCancer Biology